肺炎ワクチンの世界市場:ワクチン種類別(肺炎球菌複合ワクチン、肺炎球菌多糖ワクチン)、製品種類別(Prevnar 13、Synflorix、Pneumovax 23)、セクター別(公共、民間)、流通チャンネル別(流通パートナー企業、非政府組織・政府当局)...市場調査レポートについてご紹介

【英文タイトル】Pneumonia Vaccine Market by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine), by Product Type (Prevnar 13, Synflorix, and Pneumovax 23) and By Sector (Public and Private), by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations and Government Authorities): Opportunity Analysis and Industry Forecast, 2018–2025

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2016–2018
3.2.3. Top strategies:

3.3. Porters five forces analysis

3.3.1. Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers

3.4. Market share analysis, 2018
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Surge in prevalence of pneumonia across the globe
3.5.1.2. Rise in government focus on immunization programs for pneumonia
3.5.1.3. Increase in focus for novel pneumococcal vaccines

3.5.2. Restraints

3.5.2.1. Longer timelines required for pneumonia vaccine production
3.5.2.2. High cost associated with development of such vaccines

3.5.3. Opportunity

3.5.3.1. Development of protein-based combination pneumococcal vaccines

CHAPTER 4: PNEUMONIA VACCINES MARKET, BY VACCINE TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Pneumococcal conjugate vaccine (PCV)

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast

4.3. Pneumococcal polysaccharide vaccine (PPSV/PPV)

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast

CHAPTER 5: PNEUMONIA VACCINES MARKET, BY PRODUCT TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Prevnar 13

5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast

5.3. Synflorix

5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast

5.4. Pneumovax23

5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast

5.5. Pipeline Products

CHAPTER 6: PNEUMONIA VACCINES MARKET, BY SECTOR

6.1. Overview

6.1.1. Market size and forecast

6.2. Public sector

6.2.1. Market size and forecast

6.3. Private sector

6.3.1. Market size and forecast

CHAPTER 7: PNEUMONIA VACCINES MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.1.1. Market size and forecast

7.2. Distribution partner companies

7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast

7.3. Non-governmental Organizations (NGO)

7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast

7.4. Government Authorities

7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast

CHAPTER 8: GLOBAL PNEUMONIA MARKET, BY REGION

8.1. Overview

8.1.1. Market size and forecast

8.2. North America

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast, by type
8.2.4. Market size and forecast, by product type
8.2.5. Market size and forecast, by distribution channel
8.2.6. Market size and forecast, by sector
8.2.7. Market size and forecast, by country

8.2.7.1. The U.S. Pneumonia Vaccine Market

8.2.7.1.1. Market Size and forecast, by type
8.2.7.1.2. Market Size and forecast, by product type
8.2.7.1.3. Market Size and forecast, by distribution channel
8.2.7.1.4. Market Size and forecast, by sector

8.2.7.2. Canada Pneumonia Vaccine Market

8.2.7.2.1. Market Size and forecast, by type
8.2.7.2.2. Market Size and forecast, by product type
8.2.7.2.3. Market Size and forecast, by distribution channel
8.2.7.2.4. Market Size and forecast, by sector

8.2.7.3. Mexico Pneumonia Vaccine Market

8.2.7.3.1. Market Size and forecast, by type
8.2.7.3.2. Market Size and forecast, by product type
8.2.7.3.3. Market Size and forecast, by distribution channel
8.2.7.3.4. Market Size and forecast, by sector

8.3. Europe

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast, by type
8.3.4. Market size and forecast, by product type
8.3.5. Market size and forecast, by distribution channel
8.3.6. Market size and forecast, by sector
8.3.7. Market size and forecast, by country

8.3.7.1. Germany Pneumonia Vaccine Market

8.3.7.1.1. Market Size and forecast, by type
8.3.7.1.2. Market Size and forecast, by product type
8.3.7.1.3. Market Size and forecast, by distribution channel
8.3.7.1.4. Market Size and forecast, by sector

8.3.7.2. France Pneumonia Vaccine Market

8.3.7.2.1. Market Size and forecast, by type
8.3.7.2.2. Market Size and forecast, by product type
8.3.7.2.3. Market Size and forecast, by distribution channel
8.3.7.2.4. Market Size and forecast, by sector

8.3.7.3. UK Pneumonia Vaccine Market

8.3.7.3.1. Market Size and forecast, by type
8.3.7.3.2. Market Size and forecast, by product type
8.3.7.3.3. Market Size and forecast, by distribution channel
8.3.7.3.4. Market Size and forecast, by sector

8.3.7.4. Spain Pneumonia Vaccine Market

8.3.7.4.1. Market Size and forecast, by type
8.3.7.4.2. Market Size and forecast, by product type
8.3.7.4.3. Market Size and forecast, by distribution channel
8.3.7.4.4. Market Size and forecast, by sector

8.3.7.5. Italy Pneumonia Vaccine Market

8.3.7.5.1. Market Size and forecast, by type
8.3.7.5.2. Market Size and forecast, by product type
8.3.7.5.3. Market Size and forecast, by distribution channel
8.3.7.5.4. Market Size and forecast, by sector

8.3.7.6. Rest of Europe Pneumonia Vaccine Market

8.3.7.6.1. Market Size and forecast, by type
8.3.7.6.2. Market Size and forecast, by product type
8.3.7.6.3. Market Size and forecast, by distribution channel
8.3.7.6.4. Market Size and forecast, by sector

8.4. Asia-Pacific

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast, by type
8.4.4. Market size and forecast, by product type
8.4.5. Market size and forecast, by distribution channel
8.4.6. Market size and forecast, by sector
8.4.7. Market size and forecast, by country

8.4.7.1. Japan Pneumonia Vaccine Market

8.4.7.1.1. Market Size and forecast, by type
8.4.7.1.2. Market Size and forecast, by product type
8.4.7.1.3. Market Size and forecast, by distribution channel
8.4.7.1.4. Market Size and forecast, by sector

8.4.7.2. China Pneumonia Vaccine Market

8.4.7.2.1. Market Size and forecast, by type
8.4.7.2.2. Market Size and forecast, by product type
8.4.7.2.3. Market Size and forecast, by distribution channel
8.4.7.2.4. Market Size and forecast, by sector

8.4.7.3. India Pneumonia Vaccine Market

8.4.7.3.1. Market Size and forecast, by type
8.4.7.3.2. Market Size and forecast, by product type
8.4.7.3.3. Market Size and forecast, by distribution channel
8.4.7.3.4. Market Size and forecast, by sector

8.4.7.4. Rest of Asia-Pacific Pneumonia Vaccine Market

8.4.7.4.1. Market Size and forecast, by type
8.4.7.4.2. Market Size and forecast, by product type
8.4.7.4.3. Market Size and forecast, by distribution channel
8.4.7.4.4. Market Size and forecast, by sector

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast, by type
8.5.4. Market size and forecast, by product type
8.5.5. Market size and forecast, by distribution channel
8.5.6. Market size and forecast, by sector
8.5.7. Market size and forecast, by country

8.5.7.1. Brazil Pneumonia Vaccine Market

8.5.7.1.1. Market Size and forecast, by type
8.5.7.1.2. Market Size and forecast, by product type
8.5.7.1.3. Market Size and forecast, by distribution channel
8.5.7.1.4. Market Size and forecast, by sector

8.5.7.2. South Africa Pneumonia Vaccine Market

8.5.7.2.1. Market Size and forecast, by type
8.5.7.2.2. Market Size and forecast, by product type
8.5.7.2.3. Market Size and forecast, by distribution channel
8.5.7.2.4. Market Size and forecast, by sector

8.5.7.3. Saudi Arabia Pneumonia Vaccine Market

8.5.7.3.1. Market Size and forecast, by type
8.5.7.3.2. Market Size and forecast, by product type
8.5.7.3.3. Market Size and forecast, by distribution channel
8.5.7.3.4. Market Size and forecast, by sector

8.5.7.4. Rest of LAMEA Pneumonia Vaccine Market

8.5.7.4.1. Market Size and forecast, by type
8.5.7.4.2. Market Size and forecast, by product type
8.5.7.4.3. Market Size and forecast, by distribution channel
8.5.7.4.4. Market Size and forecast, by sector

CHAPTER 9: COMPANY PROFILES

9.1. GLAXOSMITHKLINE PLC.

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product Portfolio
9.1.5. Business performance

9.2. LG CHEM LTD.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance

9.3. MERCK & CO., INC.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product Portfolio
9.3.5. Business performance

9.4. PANACEA BIOTEC LIMITED

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance

9.5. PFIZER INC.

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance

9.6. PNUVAX INCORPORATED

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Product portfolio

9.7. SERUM INSTITUTE OF INDIA PVT. LTD.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Product portfolio

9.8. SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD. (BEIJING MINHAI BIOTECHNOLOGY CORPORATION LIMITED)

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Product portfolio

9.9. SK BIOSCIENCE

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Product portfolio

9.10. WALVAX BIOTECHNOLOGY CO., LTD.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Product Portfolio


【レポート販売概要】

■ タイトル:肺炎ワクチンの世界市場:ワクチン種類別(肺炎球菌複合ワクチン、肺炎球菌多糖ワクチン)、製品種類別(Prevnar 13、Synflorix、Pneumovax 23)、セクター別(公共、民間)、流通チャンネル別(流通パートナー企業、非政府組織・政府当局)
■ 英文:Pneumonia Vaccine Market by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine), by Product Type (Prevnar 13, Synflorix, and Pneumovax 23) and By Sector (Public and Private), by Distribution Channel (Distribution Partner Companies, Non-governmental Organizations and Government Authorities): Opportunity Analysis and Industry Forecast, 2018–2025
■ 発行日:2019年5月31日
■ 調査会社:Allied Market Research
■ 商品コード:AMR9AG063
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。